FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
This article was originally published in The Gray Sheet
Executive Summary
Dutch firm Agendia's MammaPrint test for predicting breast cancer recurrence set regulatory precedent Feb. 6 when it received 510(k) clearance
You may also be interested in...
Financings In Brief
Agendia plans IPO
Financings In Brief
Agendia plans IPO
Agendia Boasts Expanded Clearance, Reimbursement For Breast Cancer Test
Gene expression test maker Agendia will ramp up its U.S. marketing efforts after gaining expanded FDA clearance and Medicare coverage for its flagship MammaPrint breast cancer recurrence test